{
    "ticker": "CALA",
    "name": "Calithera Biosciences, Inc.",
    "description": "Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics to treat cancer. Founded in 2010 and headquartered in South San Francisco, California, Calithera's mission is to improve the lives of cancer patients through innovative approaches that target key metabolic pathways in tumors. The company is known for its pioneering work in the field of cancer metabolism, particularly through its lead product candidate, CB-839, an oral inhibitor of the enzyme glutaminase. This drug aims to disrupt the reliance of certain tumors on glutamine, a nutrient that fuels their growth. Calithera is also exploring combination therapies to enhance the efficacy of existing cancer treatments. The company is committed to advancing its clinical programs, which include trials for various solid tumors and hematological malignancies. With a strong pipeline of candidates and a commitment to scientific excellence, Calithera Biosciences aims to become a leader in the oncology space, offering hope to patients who have limited treatment options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2010",
    "website": "https://www.calithera.com",
    "ceo": "Susan M. Molineaux",
    "social_media": {
        "twitter": "https://twitter.com/calithera",
        "linkedin": "https://www.linkedin.com/company/calithera-biosciences/"
    },
    "investor_relations": "https://ir.calithera.com",
    "key_executives": [
        {
            "name": "Susan M. Molineaux",
            "position": "CEO"
        },
        {
            "name": "David S. W. G. T. V. R. K. H. M. H. K. M. M.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "CB-839"
            ]
        }
    ],
    "seo": {
        "meta_title": "Calithera Biosciences, Inc. | Innovative Cancer Therapeutics",
        "meta_description": "Explore Calithera Biosciences, Inc., a leader in cancer therapy innovation. Learn about their novel treatments targeting cancer metabolism and their commitment to patient care.",
        "keywords": [
            "Calithera",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "Oncology",
            "CB-839"
        ]
    },
    "faq": [
        {
            "question": "What is Calithera Biosciences known for?",
            "answer": "Calithera Biosciences is known for its innovative cancer therapeutics, particularly its lead product candidate CB-839."
        },
        {
            "question": "Who is the CEO of Calithera?",
            "answer": "Susan M. Molineaux is the CEO of Calithera Biosciences, Inc."
        },
        {
            "question": "Where is Calithera headquartered?",
            "answer": "Calithera is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Calithera's main products?",
            "answer": "Calithera's main product candidate is CB-839, an oral inhibitor of glutaminase for cancer treatment."
        },
        {
            "question": "When was Calithera founded?",
            "answer": "Calithera was founded in 2010."
        }
    ],
    "competitors": [
        "CLVS",
        "NKTR",
        "MRNA",
        "CRSP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "BMY"
    ]
}